Insmed Incorporated (NASDAQ:INSM) Receives Average Rating of “Buy” from Analysts

Insmed Incorporated (NASDAQ:INSM) has been given an average recommendation of “Buy” by the sixteen brokerages that are presently covering the firm, Marketbeat reports. Sixteen research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $91.60.

A number of equities research analysts recently weighed in on INSM shares. Wells Fargo & Company raised their price objective on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, February 21st. Truist Financial raised their price objective on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Guggenheim reiterated a “buy” rating and set a $101.00 price target on shares of Insmed in a research report on Tuesday, February 25th. Finally, Morgan Stanley raised their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th.

Insmed Trading Up 3.2 %

Shares of NASDAQ:INSM opened at $81.55 on Wednesday. Insmed has a 12-month low of $21.92 and a 12-month high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market cap of $14.76 billion, a PE ratio of -14.59 and a beta of 1.11. The stock has a 50 day moving average of $75.08 and a 200 day moving average of $73.80.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. As a group, equities research analysts expect that Insmed will post -4.56 EPS for the current year.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at $27,079,091.58. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Martina M.D. Flammer sold 6,172 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the sale, the insider now owns 101,549 shares of the company’s stock, valued at $6,462,578.36. This trade represents a 5.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 532,207 shares of company stock valued at $41,400,465 over the last three months. 4.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. Elequin Capital LP bought a new position in Insmed during the fourth quarter worth about $28,000. Steward Partners Investment Advisory LLC increased its holdings in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 163 shares in the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management acquired a new stake in shares of Insmed during the fourth quarter worth approximately $47,000. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 411 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.